1. Home
  2. GNTX vs MIRM Comparison

GNTX vs MIRM Comparison

Compare GNTX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gentex Corporation

GNTX

Gentex Corporation

HOLD

Current Price

$23.93

Market Cap

5.2B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$91.19

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNTX
MIRM
Founded
1974
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GNTX
MIRM
Price
$23.93
$91.19
Analyst Decision
Buy
Strong Buy
Analyst Count
6
11
Target Price
$29.00
$97.55
AVG Volume (30 Days)
2.2M
833.6K
Earning Date
01-30-2026
02-25-2026
Dividend Yield
2.01%
N/A
EPS Growth
N/A
N/A
EPS
1.70
N/A
Revenue
$2,431,504,922.00
$471,794,000.00
Revenue This Year
$11.92
$54.25
Revenue Next Year
$4.87
$21.09
P/E Ratio
$14.09
N/A
Revenue Growth
3.00
53.66
52 Week Low
$20.28
$36.88
52 Week High
$29.38
$93.70

Technical Indicators

Market Signals
Indicator
GNTX
MIRM
Relative Strength Index (RSI) 51.09 72.63
Support Level $23.35 $85.98
Resistance Level $24.92 $91.80
Average True Range (ATR) 0.56 3.82
MACD -0.02 1.15
Stochastic Oscillator 45.19 88.20

Price Performance

Historical Comparison
GNTX
MIRM

About GNTX Gentex Corporation

Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: